Novocure Receives FDA Rejection for Tumor Device Application

MT Newswires Live11-09

Novocure (NVCR) said Monday it received a Not Approvable Letter from the US Food and Drug Administration for its Optune Mya device to treat adults with brain metastases from non-small cell lung cancer following stereotactic radiation.

The company said the FDA determined that uncertainty about the degree of clinical benefit prevented approval of its premarket approval application but raised no concerns about the device's safety profile.

Novocure said it is evaluating the agency's feedback and plans to meet with the agency to discuss potential paths to approval that would not require additional clinical studies.

The company added that there is no guarantee the discussions or any future submissions will result in approval.

Shares of the company fell more than 4% in Monday's premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment